BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
German mid-sized firms gloomy on outlook, survey finds - 2Meet the Artemis crew in NASA's first astronaut mission to the moon in more than a half-century
- 3The World's Dazzling Regular Miracles
- 4NASA Artemis II tracker: Where is the Orion now and when will it reach the moon?
- 5Norovirus is spreading earlier again this year, wastewater data shows
- Volkswagen Just Revealed a Massive Range-Extended SUV for China, and America Isn’t Getting It
- How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
- Space debris: will it take a catastrophe for nations to take the issue seriously?
- JFK's granddaughter Tatiana Schlossberg reveals terminal cancer diagnosis
- The Best Web-based Courses for Ability Advancement
- Jupiter and the moon take a sunset stroll on March 26. Here's how to see it
- Manual for Vegetarian Protein Powder
- Carina Nebula shines with white-blue stars | Space photo of the day for Jan. 5, 2026
- Must-See Public Parks from Around the Globe
